Alex Seelenberger
Partner @ Aurus
Alex Seelenberger is a funding round investor at Aurus focused on Biotechnology and Medical. Alex Seelenberger joined Aurus Asset Management in 2008 to lead the Venture Capital Life Science Division. Aurus BIOS, launched in 2010, has made 9 investments, with a focus on early stage development companies in biotechnology, specialty pharma, diagnostics and medical devices, agbio and industrial biotech.Previous to Aurus, Alex worked atAthelera LLC, a merger and acquisitions firm in New York, where he focused on M&As across several industries within Latin America. Additionally, he was a consultant for the Boston Consulting Group focusing primarily in pharmaceutical industry, financial services, and mining projects.Alex holds an MBA – Baker Scholar – from Harvard University and a Commercial Engineering degree from Universidad de Chile.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 10%
Last updated:
For AI agents: llms.txt
Industries Alex Seelenberger invests in
Stages Alex Seelenberger invests in
Countries Alex Seelenberger invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 7 (35%)
- Medical 3 (15%)
- Health Care 3 (15%)
- Pharmaceutical 2 (10%)
- Fuel 1 (5%)
Stage
- Funding Round 8 (40%)
- Venture - Series Unknown 2 (10%)
- Series A 1 (5%)
- Series B 1 (5%)
Country
- United States 5 (25%)
- Chile 4 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Levita Magnetics
|
As a medical device start up, Levita Magnetics is passionate about developing innovative magnetic surgical platforms that serve as a catalyst in the continued evolution of less invasive surgery.The company's mission is to enhance patient outcomes by minimizing the footprint of surgical procedures across multiple indications and broadpatient populations. It's innovative magnetic surgical platform, called Magnetic Surgery®, is the next step in the evolution of less invasive surgery. | $1M / Jul 19, 2019 | |
EchoPixel
|
EchoPixel, Inc. develops medical imaging devices. The company develops a non-invasive colon cancer screening solution that enables doctors and radiologists to use computed tomography (CT) images of a patient’s abdomen and display a 3D model of a patient’s colon. With this tool, any medical professional can examine the entire colon by using anavigate and detect approach to identify most polyps or other abnormalities, the cause of cancer. The company was incorporated in 2012 and is based in San Jose, California. | $8.5M / Series A / Oct 19, 2017 | |
Algenis
|
Algenis is an known in the R&D of natural sodium channel blocker molecules derived from microalgae.The company aims to be a leader in the production, formulation, and clinical development of bioactive molecules produced by marine microalgae with medical application as muscle relaxant and analgesic, as well as for the treatment of neurologicaldiseases. Algenis' strategy is to commercialize our products through licensing, co-development, or direct sales options. Algenis' first therapeutic indication is for the treatment and healing of anal fissures. | Venture - Series Unknown / Jun 30, 2016 | |
|
EchoPixel
|
EchoPixel, Inc. develops medical imaging devices. The company develops a non-invasive colon cancer screening solution that enables doctors and radiologists to use computed tomography (CT) images of a patient’s abdomen and display a 3D model of a patient’s colon. With this tool, any medical professional can examine the entire colon by using anavigate and detect approach to identify most polyps or other abnormalities, the cause of cancer. The company was incorporated in 2012 and is based in San Jose, California. | $1.7M / Venture - Series Unknown / Jan 29, 2016 | |
|
Algenis
|
Algenis is an known in the R&D of natural sodium channel blocker molecules derived from microalgae.The company aims to be a leader in the production, formulation, and clinical development of bioactive molecules produced by marine microalgae with medical application as muscle relaxant and analgesic, as well as for the treatment of neurologicaldiseases. Algenis' strategy is to commercialize our products through licensing, co-development, or direct sales options. Algenis' first therapeutic indication is for the treatment and healing of anal fissures. | Aug 20, 2015 | |
Andes Biotechnologies
|
Andes Biotechnologies is a leading nucleic acid-based drug discovery and development company focused on solid tumor cancers. The Company has discovered two novel families of long non-coding RNAs: sense (S-RNA) and antisense (AS-RNA). Both are present in all human cells, are synthesized in the mitochondria and migrate to the nucleus.Theproprietary technology developed by Andes Biotechnologies is based on oligonucleotide drugs that target the novel long non-coding regulatory RNAs in tumor cells inducing apoptosis.Andes Biotechnologies has an active investigational new drug (IND) application in the United States and is currently engaged in the clinical development of its lead drug Andes-1537.Andes Biotechnologies is supported by a proven and experienced management team, a robust network of key national and international collaborators in the cancer field, and has an extensive intellectual property portfolio.Andes Biotechnologies was founded in 2008 and is located in Santiago, Chile. | Dec 23, 2014 | |
Kinostics
|
Kinostics is developing a non-invasive diagnostic test for the detection of Acute Kidney Injury (AKI) at sub-clinical stages. | Aug 12, 2014 | |
|
Levita Magnetics
|
As a medical device start up, Levita Magnetics is passionate about developing innovative magnetic surgical platforms that serve as a catalyst in the continued evolution of less invasive surgery.The company's mission is to enhance patient outcomes by minimizing the footprint of surgical procedures across multiple indications and broadpatient populations. It's innovative magnetic surgical platform, called Magnetic Surgery®, is the next step in the evolution of less invasive surgery. | Aug 08, 2014 | |
Trigemina
|
Trigemina, Inc. develops non-opiate drug formulations and delivery systems for the pain therapy. The company’s products include TI-001, an intranasal oxytocin that targets chronic and sub-acute head pain; and TI-002, a non-opioid treatment that addresses a range of pain, including neuropathic pain throughout the body. Its drugs are delivered viathe nasal-cerebral pathway. The company was founded in 2006 and is based in Mountain View, California. | Apr 14, 2014 | |
|
Andes Biotechnologies
|
Andes Biotechnologies is a leading nucleic acid-based drug discovery and development company focused on solid tumor cancers. The Company has discovered two novel families of long non-coding RNAs: sense (S-RNA) and antisense (AS-RNA). Both are present in all human cells, are synthesized in the mitochondria and migrate to the nucleus.Theproprietary technology developed by Andes Biotechnologies is based on oligonucleotide drugs that target the novel long non-coding regulatory RNAs in tumor cells inducing apoptosis.Andes Biotechnologies has an active investigational new drug (IND) application in the United States and is currently engaged in the clinical development of its lead drug Andes-1537.Andes Biotechnologies is supported by a proven and experienced management team, a robust network of key national and international collaborators in the cancer field, and has an extensive intellectual property portfolio.Andes Biotechnologies was founded in 2008 and is located in Santiago, Chile. | Mar 10, 2014 | |
| See all 20 investments → | |||
Co-Investors
About Aurus
Aurus is a Chilean investment firm that manages funds in the venture capital, real estate, and capital markets.We are pioneers in Latin America’s Venture Capital industry, dedicated to developing the ecosystem and investing in the region’s most impressive talent, and scalable technologies. We believe that Chile is the best platform in which toinvest in our region because of its investment friendly policies, commitment to innovation, and industry leadership.As local investors, we realize where the biggest transformations are occurring. We add value to our portfolio companies through experience, insights, best practices, and network. Our investment decisions are aided by the advice of outstanding advisory committees for each of the funds. All of them are also LPs in the fund and a valuable resource to Aurus and our investees, both in evaluating a prospective investment and later adding value to them through our mentoring program.
Aurus Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alejandro Furman
Partner
|
|||
|
Alex Seelenberger
Partner
|
|||
Bernardita Araya
Senior Asociate
|
|||
Cesar Munoz
Team Member
|
|||
Raimundo Cerda
Managing Partner & CEO
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Alex Seelenberger invest in?
Alex Seelenberger invests primarily in Biotechnology, Medical and Health Care startups, most often at Funding Round and Venture - Series Unknown stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Alex Seelenberger?
Public channels for Alex Seelenberger include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Alex Seelenberger last invest?
The most recent investment recorded for Alex Seelenberger closed in Jul 2019. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
